A.C. Camargo Cancer Center

AI Tools Show Promise in Improving HER2 Breast Cancer Classification and Treatment Eligibility

- A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized. - The Digital PATH Project, involving 31 partners including pharmaceutical companies and academic centers, validated AI diagnostic technologies using 1,100 breast cancer tissue samples to assess consistency in HER2 expression identification. - AI tools particularly enhanced detection of HER2-low and HER2-ultralow expression levels, reducing misclassification by 24.4% and potentially expanding treatment eligibility for antibody-drug conjugates to patients previously classified as HER2-negative.